PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26447442-5 2015 Patients undergoing percutaneous coronary intervention for acute coronary syndromes who are known to be poor metabolizers of CYP2C19 should consider alternate antiplatelet therapy (e.g., ticagrelor, prasugrel). Ticagrelor 187-197 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 125-132 26398625-4 2015 CYP2C19 LOF allele(s) carriers who were poor metabolizers received prasugrel or ticagrelor. Ticagrelor 80-90 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 0-7 24856643-8 2014 The benefits of prasugrel and ticagrelor compared to clopidogrel treated patients in terms of platelet inhibition were more pronounced in CYP2C19*2 carriers. Ticagrelor 30-40 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 138-145 26550258-3 2015 OBJECTIVE: We aimed to assess a pharmacogenetic approach of doubling dose clopidogrel compare with standard dose of ticagrelor among carriers with the CYP2C19*2 homozygotes. Ticagrelor 116-126 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 151-158 26550258-4 2015 MATERIALS AND METHODS: We compared ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) with clopidogrel (600 mg loading dose, 150 mg daily thereafter) for the prevention of cardiovascular events in CYP2C19*2 homozygotes patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. Ticagrelor 35-45 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 209-216 26550258-8 2015 After the first 600 mg loading dose of clopidogrel, patients carrying two CYP2C19*2 allele had weaker PRU inhibition (39.8+-37.4 vs 27.9+-12.4; P = 0.001) and more bleeding adverse events (20.5% vs. 7.1%; hazard ratio = 2.88; 95% [CI], 1.34-6.15; P = 0.001) compared to those taking standard dose of ticagrelor. Ticagrelor 300-310 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 74-81 26550258-10 2015 This study suggests that ticagrelor may be much better than doubling dose clopidogrel in patients with CYP2C19*2 in according to platelet reactivity monitoring. Ticagrelor 25-35 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 103-110 26108379-11 2015 Initial market share for clopidogrel, prasugrel, and ticagrelor was 93%, 5%, and 2%, respectively; however, use of CYP2C19 genotyping is expected to shift market share from clopidogrel to either prasugrel or ticagrelor. Ticagrelor 208-218 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 115-122 26108379-15 2015 CONCLUSIONS: Important financial benefits may be realized through use of genotype-guided antiplatelet therapy to reserve prasugrel or ticagrelor use for patients with reduced CYP2C19 activity to avoid costs associated with adverse cardiac events. Ticagrelor 134-144 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 175-182 25823779-5 2015 CYP2C19 intermediate or poor metabolizer phenotype was among the strongest predictors for selecting prasugrel or ticagrelor as maintenance therapy (p < 0.001), and was the only significant predictor of a change in therapy (p < 0.001). Ticagrelor 113-123 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 0-7 24406062-7 2014 In general, concomitant administration of P2Y12 receptor antagonists and strong inhibitors or inducers of CYP3A/CYP2C19 should be performed with caution in patients treated with clopidogrel/ticagrelor. Ticagrelor 190-200 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 112-119 24279856-1 2013 AIMS: This study aims to assess the cost-effectiveness in Australia of screening CYP2C19 loss-of-function (LoF) alleles to guide selection of clopidogrel or ticagrelor for individuals with acute coronary syndrome who are likely to undergo coronary stenting. Ticagrelor 157-167 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 81-88 21177984-5 2011 Ticagrelor moderately inhibited CYP2C9 activity in human liver microsomes with an IC(50) of 10.5 muM, while exhibiting little or no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP2E1. Ticagrelor 0-10 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 170-177 21079055-0 2010 First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Ticagrelor 102-112 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 39-46 21079055-1 2010 BACKGROUND: The influence of cytochrome P450 (CYP) 2C19 genotype on platelet function in patients treated with ticagrelor versus clopidogrel is unknown. Ticagrelor 111-121 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 29-55 35396752-12 2022 WHAT IS NEW AND CONCLUSIONS: For patients carrying CYP2C19 LOF alleles after PCI, ticagrelor may be better than high-dose clopidogrel in reducing the risk of MACEs, while dyspnoea incidents should be alerted. Ticagrelor 82-92 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 51-58 33744207-14 2021 CONCLUSIONS: The effect of ticagrelor or prasugrel compared with clopidogrel in reducing ischemic events in patients with CAD who predominantly undergo PCI is based primarily on the presence of CYP2C19 loss-of-function carrier status. Ticagrelor 27-37 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 194-201 35226525-0 2022 In patients with stroke or TIA and CYP2C19 loss-of-function alleles, ticagrelor vs. clopidogrel reduced 90-d stroke. Ticagrelor 69-79 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 35-42 33744207-1 2021 OBJECTIVES: The aim of this study was to examine the effect of CYP2C19 genotype on clinical outcomes in patients with coronary artery disease (CAD) who predominantly underwent percutaneous coronary intervention (PCI), comparing those treated with ticagrelor or prasugrel versus clopidogrel. Ticagrelor 247-257 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 63-70 33744207-2 2021 BACKGROUND: The effect of CYP2C19 genotype on treatment outcomes with ticagrelor or prasugrel compared with clopidogrel is unclear. Ticagrelor 70-80 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 26-33 33744207-3 2021 METHODS: Databases through February 19, 2020, were searched for studies reporting the effect of CYP2C19 genotype on ischemic outcomes during ticagrelor or prasugrel versus clopidogrel treatment. Ticagrelor 141-151 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 96-103 33744207-11 2021 Ticagrelor and prasugrel compared with clopidogrel resulted in a significant reduction in ischemic events (relative risk: 0.70; 95% confidence interval: 0.59 to 0.83) in CYP2C19 loss-of-function carriers but not in noncarriers (relative risk: 1.0; 95% confidence interval: 0.80 to 1.25). Ticagrelor 0-10 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 170-177 35300607-0 2022 Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. Ticagrelor 111-121 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 10-17 35300607-1 2022 BACKGROUND: Studies show inconsistent results regarding the impact of CYP2C19 genotype on the pharmacodynamics (PD) and clinical outcomes of ticagrelor. Ticagrelor 141-151 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 70-77 35300607-2 2022 With the implementation of genotype-guided individualized antiplatelet therapy, the association between CYP2C19 polymorphism and the efficacy and safety of ticagrelor for patients is still worthy of exploring and studying. Ticagrelor 156-166 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 104-111 35300607-13 2022 CONCLUSIONS: This qualitative and quantitative study suggested Asian patients carrying any CYP2C19 LOF allele might have a lower risk of bleeding events comparing with no LOF allele carriers when treated with ticagrelor. Ticagrelor 209-219 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 91-98 32664772-0 2021 Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Ticagrelor 98-108 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 47-54 32664772-6 2021 It was demonstrated that patients treated with prasugrel or ticagrelor significantly reduced the risk of MACEs (RR 0.58; 95% CI 0.45-0.76; P<0.0001) as compared to patients with clopidogrel where both groups carrying CYP2C19 LoF alleles. Ticagrelor 60-70 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 217-224 33551797-17 2020 Conclusion: This study confirms that efficiently returned CYP2C19 genotype results did partially guide cardiologists to prescribe ticagrelor for patients with a LOF allele, and that clopidogrel had a higher risk of MACCE than ticagrelor in these patients, which provides support for the implementation of CYP2C19 gene-guided antiplatelet therapy in clinical practice. Ticagrelor 130-140 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 58-65 32675750-0 2020 Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared to Ticagrelor in PCI-Treated ACS Patients. Ticagrelor 110-120 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 13-20 33411687-8 2020 Our findings showed that ticagrelor/aspirin therapy possessed greater platelet inhibition and more rapid onset in platelet inhibition compared with clopidogrel/aspirin therapy both in carriers and non-carriers of CYP2C19 lose-of-function alleles with acute minor stroke or TIA. Ticagrelor 25-35 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 213-220 33065552-10 2020 Ticagrelor was superior to clopidogrel in inhibiting platelet reactivity measured by TEG platelet mapping among patients with acute minor stroke or TIA, particularly in carriers of the CYP2C19 LOF alleles. Ticagrelor 0-10 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 185-192 32675750-9 2020 PCI-treated ACS patients with diabetes and CYP2C19 LOF alleles are at a higher risk of recurrent ACS and high PRI/MPA, when treated with clopidogrel VS. ticagrelor, but almost comparable outcomes are recorded in the absence of one or the two risk factors. Ticagrelor 153-163 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 43-50 32840598-14 2020 Of 1849 with CYP2C19 LOF variants, 764 of 903 (85%) assigned to genotype-guided therapy received ticagrelor, and 932 of 946 (99%) assigned to conventional therapy received clopidogrel. Ticagrelor 97-107 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 13-20 32840598-7 2020 CYP2C19 LOF carriers were prescribed ticagrelor and noncarriers clopidogrel. Ticagrelor 37-47 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 0-7 32140798-0 2020 Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention. Ticagrelor 0-10 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 51-58 32320492-0 2020 Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: A systemic review and meta-analysis. Ticagrelor 56-66 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 122-129 32320492-12 2020 CONCLUSION: CYP2C19 reduced-metabolizers can expect better clinical outcome on using prasugrel or ticagrelor rather than clopidogrel. Ticagrelor 98-108 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 12-19 32493215-7 2020 Carriers of a CYP2C19*2 loss-of-function allele receive prasugrel or ticagrelor, while non-carriers are treated with clopidogrel. Ticagrelor 69-79 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 14-21 32266041-1 2020 The aim of the study was to compare the clinical efficacy and safety of ticagrelor and clopidogrel in patients with coronary heart disease one year after percutaneous coronary intervention (PCI), and to explore their association with the CYP2C19 gene polymorphism. Ticagrelor 72-82 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 238-245 32266041-12 2020 Efficacy of clopidogrel was reduced in patients with very slow CYP2C19 genotype while bleeding complications were higher in patients with fast CYP2C19 genotype receiving ticagrelor. Ticagrelor 170-180 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 143-150 32140798-1 2020 PURPOSE: To compare the risk of cardiovascular events between patients with two CYP2C19 loss-of-function alleles who were prescribed ticagrelor or clopidogrel after percutaneous coronary intervention (PCI). Ticagrelor 133-143 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 80-87 32140798-11 2020 CONCLUSIONS: In patients with two CYP2C19 loss-of-function alleles, ticagrelor was more effective than clopidogrel in preventing cardiovascular events, while the two antiplatelet agents were associated with similar incidences of major bleeding. Ticagrelor 68-78 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 34-41 31141104-10 2019 Investigators prestipulated that they would use CYP2C19 metabolizer status to change P2Y12 inhibitor in 48.5% of genotyped clopidogrel-treated patients (n = 642 of 1324) and 5.5% of genotyped ticagrelor-treated patients (n = 93 of 1692). Ticagrelor 192-202 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 48-55 31141104-12 2019 Of patients initially treated with ticagrelor, only 1 (0.1% overall; 0.7% of all who switched) was switched based on CYP2C19 status. Ticagrelor 35-45 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 117-124 31171523-13 2019 CONCLUSION: Patients with minor stroke or transient ischaemic attack who are treated with ticagrelor plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele. Ticagrelor 90-100 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 271-278 28117433-0 2018 Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Ticagrelor 90-100 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 22-42 30936830-10 2019 Although CYP2C19 and SLCO1B1 genetic variants were related to the pharmacokinetics of ticagrelor or M8, they did not show a significant effect on the platelet function recovery in this study. Ticagrelor 86-96 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 9-16 28689434-3 2018 Moreover, the presence of a CYP2C19 loss-of-function allele is associated with an increased risk of atherothrombotic events among clopidogrel-treated patients undergoing percutaneous coronary interventions (PCI), prompting studies evaluating the use of genetic tests to identify patients who may be potential candidates for alternative platelet P2Y12 receptor inhibiting therapies (prasugrel or ticagrelor). Ticagrelor 395-405 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 28-35 27977637-1 2016 BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS). Ticagrelor 120-130 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 87-94 27977637-1 2016 BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS). Ticagrelor 132-135 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 87-94 28783717-2 2017 This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI. Ticagrelor 115-125 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 184-191 28260316-8 2017 Conclusion: The CYP2C19 gene mutation is high in the patients with AMI.The effect of antiplatelet of ticagrelor is stronger than clopidogrel, and this effect is not affected by CYP2C19 gene mutations. Ticagrelor 101-111 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 16-23